Clinical Pathology & LEAP CE in Macon, GA

Clinical Pathology & LEAP CE in Macon, GA

GVMA Traveling CE: Clinical Pathology — Dawn M. Boothe, DVM, MS, PhD, DACVIM, DACVCP

7 CE Hours
Sunday, September 23, 2018
7:30 am – 3:30 pm
Macon Marriott City Center

240 Coliseum Dr, Macon, GA 31217

Register Here

Hotel Reservations:

Call (800) 228-9290 and let them know you are with the GVMA to receive our special rate of $109 per room, per night. All reservations should be made by Monday, September 3rd, 2018. A Lodge Fee of $5.00 per room, per night will also apply.


Dawn Merton Boothe, DVM, MS, PhD
Diplomate, ACVIM (Internal Medicine), ACVCP (Clinical Pharmacology)

Dr. Boothe graduated from Texas A&M University (TAMU) in 1977 and 78 (BS), and a Doctor of Veterinary Medicine in 1980. After an internship at Auburn University, she returned to TAMU to complete an MS in Physiology , a residency in small animal internal medicine (becoming board certified in 1985), and a PhrMA Fellowship and PhD in Veterinary Clinical Pharmacology (1989). She is among the first class of diplomates in the American College of Veterinary Clinical Pharmacology (1991). In 1990, she joined TAMU in the Department of Veterinary Physiology and Pharmacology, reaching Professor in 2003. She then joined the departments of Anatomy, Physiology and Pharmacology and Clinical Sciences at Auburn University’s College of Veterinary Medicine as Professor. She directs the Clinical Pharmacology Laboratory, serving over 4000 national and international veterinary practices. She actively teaches in the 1st through 4th veterinary students, and has mentored over 31 graduate students or Clinical Pharmacology Residents. Dr. Boothe has received over $1.7M research funding as principle investigator, has authored or coauthored over 125 peer-reviewed scientific publications, 2 text books and over 60 book chapters. Major awards include a University Achievement Award in Teaching at Texas A&M University, the Jack Mara Scientific Achievement Award for Scientific Achievement (national), and at AU, graduate student mentor awards (University and College level) and the Zoetis Award for Excellence in Research. She most recently was recognized by Auburn University with an Alumni Professorship.


7:00 – 8:00 am: Registration/Check-In & Continental Breakfast

7:30 – 9:10 am: Antimicrobial Resistance Versus Virulence In Small Animals: E. Coli, The Other “Bad Bug”
Avoidance of antimicrobial resistance is best approached as a 3-D issue: Deescalate, Design and Decontaminate. The morning sessions will touch on this approach, using E. coli as the target organism. E. coli is a recognized pathogen whose mention may bring to mind the risks associated with the consumption of contaminated foods. For good reason: as a microorganism, it is a ubiquitous “superbug”. Because it is so adept at adapting to a surrounding environment, it is able to survive, causing disease is essentially any body system. It is the extra-intestinal E. coli , and specifically, uropathogens, that cause the most disease in humans and animals. Whereas in human medicine, surveillance systems monitor emerging resistance, in veterinary companion animal medicine, we have not such monitoring system. Yet, increasingly, because of emergence of resistance, our ability to empirically choose antimicrobials effective toward E. coli is becoming limited. This first session will describe the current state of antimicrobial resistance in small animal pathogens, with a focus on E. coli. Note, however, the multi-drug resistant E. coli is not necessarily a bad bug. It is the virulent, multi-drug resistant E. coli the presents the greatest challenge. This session will also discuss the role that virulence might play in the treatment of urinary tract infections.

Interpreting Culture And Susceptibility Testing: Picking The Best Bang For Your Bug
The single most important dosing regimen for avoidance of chronic urinary tract infection is probably the first. In general, if the goal of antimicrobial therapy is to resolve infection, standard dosing regimens might be acceptable. But in truth, the majority of “successes” include leaving behind a residual population of infecting microbes that are not resistant to the first choice drug. Critical to effective treatment of E. coli – resolution of clinical signs AND avoidance of resistance is appropriate collection, submission and interpretation of culture and susceptibility testing. The more “at risk” a patient is to fail initial therapy, the more important this becomes.

9:10 – 9:30 am: Morning Break

9:30 – 11:20 am: Designing the Dosing Regimen: The MIC is the KEY
The minimum inhibitory concentration (MIC) is foundation not only to the selection of the drug to which the isolate is most susceptible, but also the design of the dosing regimen. However, the MIC is a starting point. Time and concentration dependency of drug efficacy, the post antibiotic effect and the mutant prevention concentration are all clinically relevant terms which build upon the MIC and which influence the successful dosing regimen.

Treatment Of Chronic Urinary Tract Infections In The Dog: Therapeutic Alternatives
If the underlying cause of recurrent UTI is not resolved, it is likely just a matter of time before the clinician is faced with treating a multi-drug resistant urinary tract infection. The International Society of Companion Infectious Diseases has offered guidelines for treatment of UTI. These guidelines will be included in this fourth hour of discussion. Also included will be a focus on the use of drug combinations. Finally, a focus on the role of fosfomycin in treating multi-drug resistant UTI will round this morning’s sessions out.

11:20 am – 12:20 pm: Lunch Break

12:20 – 1:10 pm: The High Points Of Medical Marijuana
In the 1930’s, a decision was made that the risk of marijuana substance abuse took precedent over the benefits of marijuana as a therapeutic intervention? Was that a wise decision, made in the patient’s best interest? This session will try to offer a balanced perspective of what medical marijuana – as a biologic/herbal medicament might bring to the therapeutic table. The session will focus on the medical use of cannabinoid products, their regulation, evidence of efficacy for target diseases and delineate challenges that need to be overcome in generating scientific evidence in the veterinary medical community.

ADDED BONUS: LEAP CE will immediately follow the last session!
1:30 – 3:30 pm
Speaker: Dr. Doug Anderson, GA Poultry Lab
LEAP CE Topic: Backyard Poultry Regulations

Register Now!


Early Registration Late Registration (After 9/07)
Individual Member $215.00 $270.00
Nonmember $290.00 $365.00
Hospital Member $140.00 $140.00